课题基金 / 基金详情

PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON

PEG-INF VS INTRON A FOR PATIENTS WITH CHRONIC HEPATITIS C NAIVE TO INTERFERON
PEG-INF 与内含子 A 对比未接受过干扰素的慢性丙型肝炎患者
批准号:
6308082
负责人:
Jules Leonard Dienstag
金额:
$0.06万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-01 至 2000-11-30

项目摘要

项目成果

Jules Leonard Dienstag的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是比较三种不同剂量长效干扰素的有效性和安全性,聚乙二醇干扰素(PEG-IFN)每周注射一次与干扰素(R) a相比,干扰素(R) a是一种被批准的干扰素,每周注射三次,用于治疗以前未接受干扰素治疗的慢性丙型肝炎患者。研究人员报告说,所有患者目前都在登记,并处于48周的治疗中。现在要知道最终的反应频率是多少还为时过早。所有患者对治疗耐受良好。
英文摘要
The aim of this study is to compare the effectiveness and safety of three different doses of a long-acting interferon, polyethylene-glycol inerferon (PEG-IFN) injected once a week compared to Intron(R)A, an approved form of interferon that is injected three times a week as treatment of chronic hepatitis C in patients not treated previously with interferon. The investigators report that all patients are currently enrolled and are in the midst of their 48 weeks of therapy. It is premature to know what the ultimate frequency of response will be. All patients have tolerated therapy well.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS
  • 批准号:
    7731230
  • 项目类别:
  • 资助金额:
    $0.42万
  • 财政年份:
    2008
  • 负责人:
    Jules Leonard Dienstag
  • 依托单位:
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL
  • 批准号:
    7607023
  • 项目类别:
  • 资助金额:
    $2.96万
  • 财政年份:
    2006
  • 负责人:
    Jules Leonard Dienstag
  • 依托单位:
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL
  • 批准号:
    7205039
  • 项目类别:
  • 资助金额:
    $8.65万
  • 财政年份:
    2004
  • 负责人:
    Jules Leonard Dienstag
  • 依托单位:
THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL
  • 批准号:
    6982553
  • 项目类别:
  • 资助金额:
    $16.37万
  • 财政年份:
    2003
  • 负责人:
    Jules Leonard Dienstag
  • 依托单位:
海外基金